DPP4 and Hyperglycemia: With specific attention to alogliptin as a DPP-4 inhibitor, the U.S. Food and Drug Administration (FDA) approved three new oral alogliptin-based agents in hyperglycemia treatment, including alogliptin alone [7], alogliptin-metformin hydrochloride combination [8], and alogliptin-pioglitazone combination [9].